person · Reporting owner

HENNEY CHRISTOPHER S

Disclosed activity across 4 companies

Tapewire entity: 111704
SEC CIK: 0001242880

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Anthera Pharmaceuticals IncANTH · Entity 163677	Director	January 05, 2018	January 09, 2018
Bio Green Med Solution, Inc.CYCC · Entity 8225	Director	June 30, 2023	July 03, 2023
PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375	Director	July 14, 2021	July 16, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Anthera Pharmaceuticals Inc

Report date January 05, 2018 · Filed January 09, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05	Direct	84,705	Reported balance After 2018-01-05 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2028-01-05	Direct	84,705	Reported balance After 2018-01-05 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-01-05 · Grant · Acquired 84,705 · Balance 84,705 F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018.

Filing footnotes · ownership attribution and instrument terms

F1: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017.

F2: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018.

Bio Green Med Solution, Inc.

Report date June 30, 2023 · Filed July 03, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	39,415	Reported balance After 2023-06-30 transaction · row 1 1 source row Row 1 · 2023-06-30 · Grant · Acquired 21,219 · Balance 39,415 F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024. F2: These securities were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.59 · Expires 2033-06-30	Direct	42,438	Reported balance After 2023-06-30 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2023-06-30 · Grant · Acquired 42,438 · Balance 42,438 F2: These securities were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

Filing footnotes · ownership attribution and instrument terms

F1: The reporting person received an award of 21,219 restricted stock units on June 30, 2023, which shall vest in full on June 30, 2024.

F2: These securities were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc.

PROTHENA CORP PUBLIC LTD CO

Report date July 14, 2021 · Filed July 16, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative	Direct	0	Ending reported balance After 2021-07-14 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2021-07-14 · Exercise / conversion · Acquired 11,108 · Balance 11,108 Row 2 · 2021-07-14 · Sale · Disposed 9,108 · Balance 2,000 F1: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: The transaction was executed in multiple trades in prices ranging from $55.00 to $55.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Row 3 · 2021-07-14 · Sale · Disposed 2,000 · Balance 0 F1: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3: The transaction was executed in multiple trades in prices ranging from $56.005 to $56.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.33 · Expires 2030-05-20	Direct	0	Reported balance After 2021-07-14 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-14 · Exercise / conversion · Disposed 11,108 · Balance 0 F4: The shares subject to the option were fully vested as of the date of the exercise.

Filing footnotes · ownership attribution and instrument terms

F1: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2: The transaction was executed in multiple trades in prices ranging from $55.00 to $55.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: The transaction was executed in multiple trades in prices ranging from $56.005 to $56.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F4: The shares subject to the option were fully vested as of the date of the exercise.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Cascadian Therapeutics, Inc.

Report date March 09, 2018 · Filed March 13, 2018

Section 16 reporting ended · disclosed 2018-03-13. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2018-03-09 transaction · row 1 1 source row Row 1 · 2018-03-09 · Other · Disposed 60,185 · Balance 0 F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.
Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.36 · Expires 2026-03-16	Direct	Reported balance After 2018-03-09 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2018-03-09 · Disposition to issuer · Disposed 25,000 · Balance 0 F3: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $91,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of March 16, 2016, and the remainder vest monthly thereafter for 36 months. All shares subject to this option are fully vested.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2018-03-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-03-09 · Disposition to issuer · Disposed 13,927 · Balance 0 F4: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F5: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F6: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes.

F2: 25% of the shares subject to the option vest on the first anniversary of the grant date of March 16, 2016, and the remainder vest monthly thereafter for 36 months. All shares subject to this option are fully vested.

F3: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $91,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option.

F4: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price.

F5: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date.

F6: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 12, 2021 Filed Feb 17, 2021 18:40 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	12,000	Not disclosed Strike: $56.23	Not disclosed	Disclosure SEC source: 0001567619-21-004308 · doc1.xml · derivative · entry 5 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 12,000 shares Expires 2027-05-18 F4 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 12,000 of the issuer's ordinary shares granted to the reporting person on May 18, 2017. In exchange, the reporting person received a replacement option, for 6,315 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document
February 12, 2021 Filed Feb 17, 2021 18:40 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantEmployee Stock Option (Right to Buy) · Derivative	8,426	Not disclosed Strike: $22.85	Not disclosed	Disclosure SEC source: 0001567619-21-004308 · doc1.xml · derivative · entry 4 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,426 Underlying: Ordinary Shares · 8,426 shares Expires 2026-05-20 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 20, 2016. In exchange, the reporting person received a replacement option, for 8,426 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document
February 12, 2021 Filed Feb 17, 2021 18:40 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $42.50	Not disclosed	Disclosure SEC source: 0001567619-21-004308 · doc1.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2026-05-20 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 20, 2016. In exchange, the reporting person received a replacement option, for 8,426 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document
February 12, 2021 Filed Feb 17, 2021 18:40 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantEmployee Stock Option (Right to Buy) · Derivative	9,803	Not disclosed Strike: $22.85	Not disclosed	Disclosure SEC source: 0001567619-21-004308 · doc1.xml · derivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,803 Underlying: Ordinary Shares · 9,803 shares Expires 2025-05-22 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 22, 2015. In exchange, the reporting person received a replacement option, for 9,803 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document
February 12, 2021 Filed Feb 17, 2021 18:40 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	15,000	Not disclosed Strike: $34.04	Not disclosed	Disclosure SEC source: 0001567619-21-004308 · doc1.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 15,000 shares Expires 2025-05-22 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 15,000 of the issuer's ordinary shares granted to the reporting person on May 22, 2015. In exchange, the reporting person received a replacement option, for 9,803 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document
June 25, 2020 Filed Jun 29, 2020 22:49 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	5,200	$0.00 Strike: $4.70	$0.00	Disclosure SEC source: 0001104659-20-078123 · tm2023597d4_form4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,200 Underlying: Common Stock · 5,200 shares Expires 2030-06-25 F1 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
May 20, 2020 Filed May 22, 2020 16:40 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $11.33	$0.00	Disclosure SEC source: 0001567619-20-011035 · doc1.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2030-05-20 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day of the annual general meeting in 2021 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document
May 29, 2019 Filed May 31, 2019 20:39 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	18,750	$0.00 Strike: $0.64	$0.00	Disclosure SEC source: 0001144204-19-029258 · tv522822_form4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 18,750 shares Expires 2029-05-29 F1 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
May 22, 2019 Filed May 24, 2019 16:07 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantStock Option (Right to Buy) · Derivative	17,500	$0.00 Strike: $9.23	$0.00	Disclosure SEC source: 0001567619-19-012072 · doc1.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Ordinary Shares · 17,500 shares Expires 2029-05-22 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2020 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document
May 31, 2018 Filed Jun 4, 2018 21:36 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	8,576	$0.00 Strike: $1.42	$0.00	Disclosure SEC source: 0001144204-18-032720 · tv495790_form4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,576 Underlying: Common Stock · 8,576 shares Expires 2028-05-31 F1 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
May 16, 2018 Filed May 18, 2018 16:15 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $16.43	$0.00	Disclosure SEC source: 0000899243-18-013415 · doc4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2028-05-16 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2019 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerRestricted Stock Units · Derivative	13,927	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007293 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 13,927 shares Expires not disclosed F4 · derivative.exercise_price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F4 · price: Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $139,270.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price. F5 · derivative.exercise_date: The restricted stock units were granted on June 9, 2017 and vest on the one-year anniversary of the grant date. F6 · derivative.expiration_date: The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Disposition to issuerStock Option (Right to buy) · Derivative	25,000	Not disclosed Strike: $6.36	Not disclosed	Disclosure SEC source: 0000899243-18-007293 · doc4.xml · derivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2026-03-16 F3 · price: Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $91,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option. F2 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary of the grant date of March 16, 2016, and the remainder vest monthly thereafter for 36 months. All shares subject to this option are fully vested. Read SEC document
March 09, 2018 Filed Mar 13, 2018 18:01 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	OtherCommon Stock	60,185	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-18-007293 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the "Merger Agreement"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share ("Offer Price"), net to the seller in cash, without interest and less any required withholding taxes. Read SEC document
January 05, 2018 Filed Jan 9, 2018 06:32 UTC	Anthera Pharmaceuticals Inc ANTH · Entity 163677	GrantStock Option (right to buy) · Derivative	84,705	$0.00 Strike: $1.65	$0.00	Disclosure SEC source: 0001214659-18-000287 · marketforms-40684.xml · derivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,705 Underlying: Common Stock · 84,705 shares Expires 2028-01-05 F2 · derivative.exercise_date: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2018. This option vests in 12 equal monthly installments. The vesting commencement date is commensurate with the grant date of January 5, 2018. Read SEC document
January 05, 2018 Filed Jan 9, 2018 06:32 UTC	Anthera Pharmaceuticals Inc ANTH · Entity 163677	GrantStock Option (right to buy) · Derivative	84,705	$0.00 Strike: $1.65	$0.00	Disclosure SEC source: 0001214659-18-000287 · marketforms-40684.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,705 Underlying: Common Stock · 84,705 shares Expires 2028-01-05 F1 · derivative.exercise_date: This option is granted pursuant to the Company's director compensation program and is for fiscal year ending December 31, 2017. This option vests in 12 equal monthly installments. The vesting commencement date is April 27, 2017. Read SEC document
September 28, 2017 Filed Sep 29, 2017 17:15 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionStock Option (right to buy) · Derivative	900	$0.00 Strike: $6.65	$0.00	Disclosure SEC source: 0000899243-17-022965 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Ordinary Shares · 900 shares Expires 2023-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document
September 28, 2017 Filed Sep 29, 2017 17:15 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	SaleOrdinary Shares, par value $0.01 per share	900	$70.00	$63,000.00	Disclosure SEC source: 0000899243-17-022965 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. Read SEC document
September 28, 2017 Filed Sep 29, 2017 17:15 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionOrdinary Shares, par value $0.01 per share	900	$6.65	$5,985.00	Disclosure SEC source: 0000899243-17-022965 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
September 24, 2017 Filed Sep 26, 2017 17:19 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionRestricted Share Unit (RSU) · Derivative	2,375	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054013 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,375 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: The RSU was 100% vested on September 24, 2017. F3 · derivative.expiration_date: The RSU was 100% vested on September 24, 2017. Read SEC document
September 24, 2017 Filed Sep 26, 2017 17:19 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Tax withholdingCommon Stock	594	$3.94	$2,340.36	Disclosure SEC source: 0001209191-17-054013 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,185 F1 · shares: 594 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 594 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on September 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on September 22, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document
September 24, 2017 Filed Sep 26, 2017 17:19 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionCommon Stock	2,375	$0.00	$0.00	Disclosure SEC source: 0001209191-17-054013 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,779 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
July 17, 2017 Filed Jul 19, 2017 16:10 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionStock Option (right to buy) · Derivative	5,000	$0.00 Strike: $6.65	$0.00	Disclosure SEC source: 0000899243-17-018555 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Ordinary Shares · 5,000 shares Expires 2023-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document
July 17, 2017 Filed Jul 19, 2017 16:10 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	SaleOrdinary Shares, par value $0.01 per share	5,000	$66.13	$330,670.50	Disclosure SEC source: 0000899243-17-018555 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $66.00 to $66.30, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document
July 17, 2017 Filed Jul 19, 2017 16:10 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionOrdinary Shares, par value $0.01 per share	5,000	$6.65	$33,250.00	Disclosure SEC source: 0000899243-17-018555 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 24, 2017 Filed Jun 27, 2017 17:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionRestricted Share Unit (RSU) · Derivative	9,058	$0.00	$0.00	Disclosure SEC source: 0001209191-17-042005 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: The RSU was 100% vested on June 24, 2017. F3 · derivative.expiration_date: The RSU was 100% vested on June 24, 2017. Read SEC document
June 24, 2017 Filed Jun 27, 2017 17:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Tax withholdingCommon Stock	2,265	$3.78	$8,561.70	Disclosure SEC source: 0001209191-17-042005 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,404 F1 · shares: 2,265 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 2,265 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 24, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 23, 2017, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document
June 24, 2017 Filed Jun 27, 2017 17:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionCommon Stock	9,058	$0.00	$0.00	Disclosure SEC source: 0001209191-17-042005 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,669 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 12, 2017 Filed Jun 13, 2017 16:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionRestricted Share Unit (RSU) · Derivative	2,148	$0.00	$0.00	Disclosure SEC source: 0001209191-17-039497 · doc4.xml · derivative · entry 4 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,148 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F4 · derivative.exercise_date: The RSU was 100% vested on June 12, 2017. F4 · derivative.expiration_date: The RSU was 100% vested on June 12, 2017. Read SEC document
June 12, 2017 Filed Jun 13, 2017 16:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Tax withholdingCommon Stock	537	$3.34	$1,793.58	Disclosure SEC source: 0001209191-17-039497 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,611 F1 · shares: 537 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F1 · price: 537 shares of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 12, 2017, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 12, 2017 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. Read SEC document
June 12, 2017 Filed Jun 13, 2017 16:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionCommon Stock	2,148	$0.00	$0.00	Disclosure SEC source: 0001209191-17-039497 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
June 09, 2017 Filed Jun 13, 2017 16:39 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	GrantRestricted Share Unit (RSU) · Derivative	13,927	$0.00	$0.00	Disclosure SEC source: 0001209191-17-039497 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,927 Underlying: Common Stock · 13,927 shares Expires not disclosed F2 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F3 · derivative.exercise_date: 100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances. F3 · derivative.expiration_date: 100% vests on the one-year anniversary of the Transaction Date, subject to acceleration under certain circumstances. Read SEC document
May 30, 2017 Filed Jun 1, 2017 21:04 UTC	Bio Green Med Solution, Inc. CYCC · Entity 8225	GrantStock Option (right to buy) · Derivative	2,000	$0.00 Strike: $4.38	$0.00	Disclosure SEC source: 0001571049-17-005585 · t1701732_x3-f4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2027-05-30 F1 · price: These options were granted to Dr. Henney for his services as a member of the board of directors of Cyclacel Pharmaceuticals, Inc. Read SEC document
May 18, 2017 Filed May 19, 2017 16:07 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	GrantStock Option (right to buy) · Derivative	12,000	$0.00 Strike: $56.23	$0.00	Disclosure SEC source: 0000899243-17-013899 · doc4.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Ordinary Shares · 12,000 shares Expires 2027-05-18 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of the first anniversary of the grant date or the day prior to the annual general meeting in 2018 of the Issuer's shareholders, assuming continuous service as a director until such vesting date. Read SEC document
February 27, 2017 Filed Mar 1, 2017 16:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionStock Option (right to buy) · Derivative	5,989	$0.00 Strike: $6.65	$0.00	Disclosure SEC source: 0000899243-17-005786 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Ordinary Shares · 5,989 shares Expires 2023-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document
February 27, 2017 Filed Mar 1, 2017 16:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	SaleOrdinary Shares, par value $0.01 per share	5,989	$57.16	$342,350.40	Disclosure SEC source: 0000899243-17-005786 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $57.00 to $57.80, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 27, 2017 Filed Mar 1, 2017 16:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionOrdinary Shares, par value $0.01 per share	5,989	$6.65	$39,826.85	Disclosure SEC source: 0000899243-17-005786 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,989 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 17, 2017 Filed Feb 22, 2017 17:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionStock Option (right to buy) · Derivative	4,011	$0.00 Strike: $6.65	$0.00	Disclosure SEC source: 0000899243-17-004967 · doc4.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,989 Underlying: Ordinary Shares · 4,011 shares Expires 2023-03-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document
February 17, 2017 Filed Feb 22, 2017 17:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	SaleOrdinary Shares, par value $0.01 per share	4,011	$57.06	$228,880.50	Disclosure SEC source: 0000899243-17-004967 · doc4.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5 1 trading plan adopted by the Reporting Person. F2 · price: The transaction was executed in multiple trades in prices ranging from $57.00 to $57.26, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document
February 17, 2017 Filed Feb 22, 2017 17:05 UTC	PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375	Exercise / conversionOrdinary Shares, par value $0.01 per share	4,011	$6.65	$26,673.15	Disclosure SEC source: 0000899243-17-004967 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,011 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 30, 2017 Filed Feb 1, 2017 16:38 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	PurchaseCommon Stock	25,324	$4.11	$103,972.75	Disclosure SEC source: 0001209191-17-006724 · doc4.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: Represents the weighted average sales price per share. The shares sold at prices ranging from $3.8047 to $4.14 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the issuer, or a security holder of the issuer. Read SEC document
December 08, 2016 Filed Dec 8, 2016 18:52 UTC	Anthera Pharmaceuticals Inc ANTH · Entity 163677	GrantStock Option (right to buy) · Derivative	83,910	$0.00 Strike: $2.00	$0.00	Disclosure SEC source: 0001214659-16-015273 · marketforms-37333.xml · derivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,910 Underlying: Common Stock · 83,910 shares Expires 2026-12-08 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments from the grant date of December 8, 2016. This stock option is fully exercisable on December 8, 2017. F1 · derivative.underlying_shares: The stock option vests and becomes exercisable in 12 equal monthly installments from the grant date of December 8, 2016. This stock option is fully exercisable on December 8, 2017. Read SEC document
June 06, 2016 Filed Feb 10, 2017 16:40 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionRestricted Share Unit (RSU) · Derivative	2,723	$0.00	$0.00	Disclosure SEC source: 0001209191-17-009563 · doc5.xml · derivative · entry 3 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Approximately 75% of each RSU represents a contingent right to receive approximately 0.75 share of the issuer's Common Stock upon vesting and approximately 25% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs. F1 · shares: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. F5 · derivative.exercise_date: The RSU was 100% vested on June 6, 2016. F5 · derivative.expiration_date: The RSU was 100% vested on June 6, 2016. Read SEC document
June 06, 2016 Filed Feb 10, 2017 16:40 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Tax withholdingCommon Stock	681	$7.38	$5,025.78	Disclosure SEC source: 0001209191-17-009563 · doc5.xml · nonDerivative · entry 2 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F2 · shares: 681 shares (which number reflects post-reverse split shares) of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 6, 2016, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 6, 2016, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F2 · price: 681 shares (which number reflects post-reverse split shares) of the restricted share unit ("RSU") grant, which represent approximately 25% of the shares underlying the RSU grant that vested on June 6, 2016, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on June 6, 2016, the most recent date prior to the vesting date on which the issuer's Common Stock was traded, to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person. F3 · price: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The price above reflects the reverse stock split. Read SEC document
June 06, 2016 Filed Feb 10, 2017 16:40 UTC	Cascadian Therapeutics, Inc. CASC · Entity 168341	Exercise / conversionCommon Stock	2,723	$0.00	$0.00	Disclosure SEC source: 0001209191-17-009563 · doc5.xml · nonDerivative · entry 1 HENNEY CHRISTOPHER S · CIK 0001242880 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,861 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Effective as of November 29, 2016, the issuer effected a 6-for-1 reverse split of its common stock. The number of shares above reflects the reverse stock split. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.